NIH Launches First Human Trial of Purified Mitragynine MG001 for Opioid Use Disorder

Why it matters

For the first time, a federal agency is testing a purified kratom alkaloid in humans, potentially opening a path to FDA-regulated treatment for opioid use disorder. The trial distinguishes pharmaceutical-grade mitragynine from the concentrated 7-OH products facing a DEA ban.

The big picture

NIDA and University of Florida researchers obtained an FDA Investigational New Drug (IND) approval for MG001, a purified mitragynine formulation. Simultaneous federal action against high-potency 7-OH products underscores the regulatory split: one alkaloid is being banned, while another is entering Phase 1 human trials. The opioid crisis context makes this especially significant: over 80,000 Americans died of opioid-related overdoses in 2024 alone.

Key findings

• Phase 1 trial NCT07204171 will enroll 32 healthy adult volunteers with a recent history of opioid use
• Estimated start date is September 2026, with completion projected around April 2027
• The trial measures safety, tolerability, and pharmacokinetics — not efficacy
• MG001 is a pharmaceutical-grade, single-molecule preparation, not a retail kratom product
• NIDA Director Joni Rutter cited positive preclinical animal data as the basis for advancing to human testing

What they say

"We've seen the potential of mitragynine in the lab, and now we're finally able to examine its potential in people." — Joni Rutter, PhD, Director, NIH National Center for Advancing Translational Sciences

Bottom line

The first federally sponsored human trial of a purified kratom alkaloid begins this fall — a milestone that sets pharmaceutical mitragynine on a separate legal and scientific track from the retail 7-OH products being removed from shelves.